About GlyCardial Diagnostics
GlyCardial Diagnostics is a company based in Barcelona (Spain) founded in 2017 by Judit Cubedo, Gemma Vilahur, Teresa Padro, and Lina Badimon. GlyCardial Diagnostics has raised $2.8 million across 7 funding rounds from investors including EIT Health, Ship2B and European Union. GlyCardial Diagnostics offers products and services including iSCOR. GlyCardial Diagnostics operates in a competitive market with competitors including Conavi, Acarix, Ionetix, Infraredx and Cleveland HeartLab, among others.
- Headquarter Barcelona, Spain
- Founders Judit Cubedo, Gemma Vilahur, Teresa Padro, Lina Badimon
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.8 M (USD)
in 7 rounds
-
Latest Funding Round
$56.62 K (USD), Grant
Dec 31, 2021
-
Investors
EIT Health
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GlyCardial Diagnostics
GlyCardial Diagnostics offers a comprehensive portfolio of products and services, including iSCOR.
Biomarker for early detection of cardiac ischemia via blood analysis
Funding Insights of GlyCardial Diagnostics
GlyCardial Diagnostics has successfully raised a total of $2.8M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $56.62 thousand completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GlyCardial Diagnostics
GlyCardial Diagnostics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include EIT Health, Ship2B and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Healthcare startups are accelerated and incubated through specialized programs.
|
Locked | Locked | Locked | |
|
Social impact investments are facilitated through four acceleration programs.
|
Locked | Locked | Locked |
Investor details for GlyCardial Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GlyCardial Diagnostics
Investment portfolio details for GlyCardial Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GlyCardial Diagnostics
Detailed financials for GlyCardial Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Glycardial Diagnostics Comparisons
Peer comparison for GlyCardial Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GlyCardial Diagnostics
GlyCardial Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Conavi, Acarix, Ionetix, Infraredx and Cleveland HeartLab, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Catheter-based ultrasound systems for cardiac imaging are developed.
|
|
| Locked | Locked | Locked |
A screening device for acoustic coronary artery diseases is provided.
|
|
| Locked | Locked | Locked |
Superconducting cyclotrons for PET radioisotopes are developed by Ionetix.
|
|
| Locked | Locked | Locked |
Coronary imaging and plaque detection system
|
|
| Locked | Locked | Locked |
Cardiovascular biomarkers are utilized for disease prevention and management.
|
|
| Locked | Locked | Locked |
Developer of diagnostic solution for vulnerable plaque in the coronary arteries
|
Detailed competitors of GlyCardial Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Glycardial Diagnostics
Complete news archive for GlyCardial Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GlyCardial Diagnostics
GlyCardial Diagnostics was founded in 2017.
GlyCardial Diagnostics is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Judit Cubedo is the current CEO of GlyCardial Diagnostics. They have also founded this company.
GlyCardial Diagnostics is a funded company, having raised a total of $2.8M across 7 funding rounds to date.
GlyCardial Diagnostics was established in 2017 as a spin-off from the Catalan Institute of Cardiovascular Sciences in Barcelona, Spain. Focus is placed on commercializing Apo J-Glyc as a blood-based biomarker for early detection of myocardial ischemia and prediction of patient outcomes post-event. An in vitro diagnostic device is being developed to utilize this biomarker within the cardiovascular diagnostics sector. Operations center on biomarker validation and device prototyping for clinical applications.
GlyCardial Diagnostics offers iSCOR.
GlyCardial Diagnostics has 6 investors. Key investors include EIT Health, Ship2B, European Union, EIC Fund, and Caixa Capital Risc.